New Drug Approvals Archive

Get news by email or subscribe to our news feeds.

January 2003

January 30

Amevive (alefacept)

Date of Approval: January 30, 2003
Company: Biogen, Inc
Treatment for: Psoriasis

Amevive (alefacept) is a selective immunomodulating antipsoriatic agent used to treat moderate to severe chronic plaque psoriasis.

Hide
(web4)